New triple therapy takes on resistant ovarian cancer
NCT ID NCT05467670
First seen Mar 11, 2026 · Last updated May 17, 2026 · Updated 10 times
Summary
This study tests a new combination of drugs for people with ovarian cancer that has come back and no longer responds to platinum-based chemotherapy. The treatment adds ALX148 (which targets a protein called CD47 on cancer cells) to standard chemotherapy (liposomal doxorubicin) and an immunotherapy drug (pembrolizumab). The goal is to see if this mix can shrink tumors or slow the cancer. The study enrolled 16 adults with specific types of ovarian cancer and is currently active but not recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.